Tundra Space

Tundra Space

Clinical Research Directory

Browse clinical research sites, groups, and studies.

Back to Studies
RECRUITING
NCT07567846
PHASE1/PHASE2

A Study Evaluating the Safety, Pharmacokinetics, and Preliminary Activity of GDC-1261 in Participants With Advanced or Metastatic Prostate Cancer

Sponsor: Genentech, Inc.

View on ClinicalTrials.gov

Summary

The purpose of this study is to evaluate the safety, pharmacokinetics (PK), and preliminary activity of GDC-1261 in participants with advanced or metastatic prostate cancer. It's also to identify a recommended dose(s) and regimen for GDC-1261 for subsequent studies.

Official title: A Phase I/II Dose-escalation and Expansion Study Evaluating the Safety, Pharmacokinetics, and Preliminary Activity of GDC-1261 in Patients With Advanced or Metastatic Prostate Cancer

Key Details

Gender

MALE

Age Range

18 Years - Any

Study Type

INTERVENTIONAL

Enrollment

260

Start Date

2026-04-29

Completion Date

2027-12-30

Last Updated

2026-07-09

Healthy Volunteers

No

Interventions

DRUG

GDC-1261

Participants will receive GDC-1261 as per the schedule described in the protocol.

Locations (4)

Honor Health Research Institute

Scottsdale, Arizona, United States

Sarah Cannon Research Institute

Nashville, Tennessee, United States

St Vincent's Hospital Sydney

Darlinghurst, New South Wales, Australia

Austin Hospital

Heidelberg, Victoria, Australia